VIATRIS SPECIALTY receives FDA approval for the New Drug Application 219990 on July 28, 2026, with significant market implications expected to drive performance across the specialty pharmaceutical landscape. This regulatory green light underscores VIATRIS SPECIALTY’s robust pipeline capabilities and positions the company to capture new revenue streams amidst increasing demand for innovative therapeutic solutions.